Antimicrobial Susceptibility Testing Market Outlook Report: Latest Trends and Growth Opportunities by Region

Published On: Jan, 2025
|
Pages: 161

"The Global Antimicrobial Susceptibility Testing Market Size was valued at USD 4.0 billion in 2024 and is projected to reach USD 4.2 billion in 2025. Worldwide sales of Antimicrobial Susceptibility Testing are expected to grow at a significant CAGR of 5.5%, reaching USD 6.9 billion by the end of the forecast period in 2034."

Antimicrobial Susceptibility Testing Market Overview

The antimicrobial susceptibility testing (AST) market is experiencing significant growth due to the rising global concern over antimicrobial resistance (AMR). AST involves testing pathogens to determine their susceptibility to various antimicrobial agents, thereby guiding effective treatment decisions. The increasing prevalence of infectious diseases and the escalating problem of drug-resistant bacteria are driving the need for effective AST solutions. These tests are crucial for identifying specific resistance patterns and ensuring the appropriate use of antibiotics in clinical settings. With healthcare systems worldwide striving to combat the spread of resistant infections, AST plays a vital role in both patient care and the broader public health agenda.

As technology advances, so too does the field of antimicrobial susceptibility testing. Modern AST systems are becoming increasingly automated, offering faster and more accurate results. This shift is driven by the need for high-throughput solutions in hospitals and diagnostic laboratories to handle large volumes of samples efficiently. Furthermore, integration with electronic health records and laboratory information management systems is enhancing the workflow and data management capabilities associated with AST. These developments are improving diagnostic timelines and the overall effectiveness of infection control programs, thereby supporting the growth of the AST market.

Latest Trends

One of the key trends in the antimicrobial susceptibility testing market is the rapid adoption of automated systems. These systems reduce human error and increase throughput, enabling laboratories to manage larger sample volumes more efficiently. Additionally, the integration of AI and machine learning technologies is becoming prevalent. These technologies enhance predictive analytics, allowing for more precise interpretation of AST results and prediction of resistance patterns. Such advancements not only streamline laboratory operations but also contribute to more targeted antibiotic stewardship programs, which are crucial in the fight against antibiotic resistance.

Another significant trend is the development of next-generation sequencing (NGS) and molecular diagnostics in AST. These technologies offer the potential for faster, more accurate detection of resistance genes compared to traditional culture-based methods. NGS, for example, can identify resistance genes directly from clinical samples without the need for culturing, significantly reducing the time to diagnosis. Molecular diagnostics are also enhancing the specificity of AST, allowing for the detection of resistance mechanisms at the genetic level, which aids in the formulation of more effective treatment strategies.

Drivers

The primary drivers of the antimicrobial susceptibility testing market include the growing prevalence of infectious diseases and the rising incidence of drug-resistant bacteria. As antibiotic resistance becomes a more pressing global health issue, the demand for effective AST solutions is increasing. Healthcare facilities are prioritizing the adoption of advanced AST technologies to ensure accurate treatment and reduce the spread of resistant infections. Moreover, government initiatives promoting antibiotic stewardship programs and improving healthcare infrastructure are further stimulating the adoption of AST systems. These programs often mandate regular monitoring and reporting of antibiotic resistance, which directly drives the demand for susceptibility testing.

Market Challenges

Despite its critical importance, the antimicrobial susceptibility testing market faces several challenges. The high cost of advanced AST systems can be a barrier for adoption, particularly in low-resource settings. Furthermore, the complexity of some modern AST technologies requires significant training and expertise, which may not be readily available in all healthcare facilities. There is also the challenge of keeping pace with rapidly evolving bacteria and resistance mechanisms, which can make existing testing methods obsolete. Additionally, regulatory hurdles in different countries can delay the introduction of new AST technologies into the market. Addressing these challenges is essential for the continued advancement and effectiveness of antimicrobial susceptibility testing practices.

Major Players in the Antimicrobial Susceptibility Testing Market


1. Bio-Rad Laboratories, Inc.
2. Becton, Dickinson and Company
3. Thermo Fisher Scientific Inc.
4. Merck KGaA
5. Agilent Technologies, Inc.
6. bioMérieux SA
7. Bruker Corporation
8. CondaLab
9. Creative Diagnostics
10. HiMedia Laboratories
11. Synbiosis
12. Danaher Corporation
13. Accelerate Diagnostics, Inc.
14. Alifax S.r.l.
15. Liofilchem S.r.l.

Market Segmentation


  • By Product:
  • Manual Testing Products
  • Automated Testing Systems
  • Consumables
  • By Method:
  • Disk Diffusion
  • Dilution
  • E-test
  • By Application:
  • Clinical Diagnostics
  • Drug Discovery and Development
  • Others
  • By End User:
  • Hospitals and Diagnostic Centers
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutes

Please fill in the form to receive the detailed Table of Contents

Get Free Sample

At OG Analysis, we understand the importance of informed decision-making in today's dynamic business landscape. To help you experience the depth and quality of our market research reports, we offer complimentary samples tailored to your specific needs.

Start Now! Please fill the form below for your free sample.

Why Request a Free Sample?

Evaluate Our Expertise: Our reports are crafted by industry experts and seasoned analysts. Requesting a sample allows you to assess the depth of research and the caliber of insights we provide.

Tailored to Your Needs: Let us know your industry, market segment, or specific topic of interest. Our free samples are customized to ensure relevance to your business objectives.

Witness Actionable Insights: See firsthand how our reports go beyond data, offering actionable insights and strategic recommendations that can drive your business forward.

Embark on your journey towards strategic decision-making by requesting a free sample from OG Analysis. Experience the caliber of insights that can transform the way you approach your business challenges.

You can purchase individual sections of this report. Explore pricing options for specific sections.

FAQ's

The Global Antimicrobial Susceptibility Testing Market is estimated to generate USD 4 billion in revenue in 2024.

The Global Antimicrobial Susceptibility Testing Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period from 2025 to 2032.

The Antimicrobial Susceptibility Testing Market is estimated to reach USD 6.1 billion by 2032.

License

Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM

Need something within your budget? NO WORRIES! WE GOT YOU COVERED!

Related Products

Medical Gas Pipeline System Market Analysis and Outlook Report: Industry Size, Share, Growth Trends, and Forecast (2025-2034)

The Medical Gas Pipeline System Market serves as a foundational element in modern healthcare infrastructure, delivering vital gases such as oxygen, nitrous oxide, medical air, and vacuum to various departments in hospitals and healthcare facilities. These systems ensure uninterrupted gas flow to operating rooms, intensive care units, emergency wards, and patient bedsides, playing a critical role in patient safety and treatment outcomes. Built on a network of pipelines, control panels, zone valves, and alarm systems, medical gas pipeline systems must comply with rigorous international standards to guarantee purity, pressure consistency, and fault tolerance. The demand for these systems is rising sharply with the global expansion of hospitals, particularly in developing regions where healthcare access is rapidly improving. Simultaneously, retrofitting and modernization projects in established hospitals are driving upgrades to digital and automated pipeline systems. In 2024, market developments have been largely shaped by growing investments in healthcare infrastructure and increased awareness of medical gas delivery safety—especially post-pandemic. Manufacturers are focusing on offering modular and scalable pipeline solutions tailored for both large urban hospitals and smaller regional clinics. Integration with centralized monitoring systems is becoming standard, allowing real-time tracking of gas flow, leakage detection, and automated alerts. There is a notable shift toward environmentally friendly systems, with some providers incorporating gas recycling or low-leakage technology to reduce waste. Governments and private hospital chains are increasingly prioritizing projects that not only meet safety codes but also improve energy efficiency and maintenance efficiency. As healthcare becomes more digitized, medical gas pipeline systems are evolving into smart, connected infrastructure—crucial not only for operational efficiency but also for clinical excellence and emergency preparedness. Key Takeaways – Medical Gas Pipeline System Market Medical gas pipeline systems are essential for the delivery of life-supporting gases and vacuum in hospitals, making them critical to patient care and clinical efficiency. Demand is increasing globally due to expanding healthcare infrastructure, particularly in emerging economies where new hospitals and clinics are being rapidly constructed. Digital integration is trending, with hospitals seeking centralized control systems for real-time monitoring, alarm management, and leak detection. Modular and customizable pipeline systems are gaining traction, allowing tailored installations that fit unique architectural and operational requirements. Energy-efficient designs and low-leakage materials are being prioritized to support sustainability goals and reduce operational gas losses. One major driver is the surge in surgical and ICU procedures requiring reliable oxygen and vacuum supply, especially post-COVID-19. Governments are mandating stricter compliance to safety standards such as NFPA 99, ISO 7396, and HTM 02-01, pushing healthcare providers to upgrade older systems. Integration with hospital building management systems (BMS) is improving operational transparency and response times in emergency scenarios. Upfront installation costs and the need for skilled labor remain key challenges for small- and medium-sized healthcare facilities. Another challenge is the logistical complexity of retrofitting existing hospitals with modern systems without disrupting ongoing medical services. North America and Europe dominate the market in terms of compliance-driven upgrades, while Asia-Pacific leads in new installations due to hospital construction booms. Manufacturers are increasingly offering turnkey services including system design, installation, and maintenance to improve customer retention and long-term engagement. Technological collaborations between medical device companies and engineering firms are enabling smarter, data-driven gas pipeline infrastructure. Hospital chains are favoring multi-site standardized pipeline systems to streamline operations and maintenance across facilities. Market players are innovating with touch-screen control panels, wireless alert systems, and predictive maintenance tools to elevate system usability and safety. Parameter Detail Base Year 2024 Estimated Year 2025 Forecast Period 2026-2032 Market Size-Units USD billion Market Splits Covered By Product Type, By Application, By End User, By Technology, By Distribution Channel Countries Covered North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) Analysis Covered Latest Trends, Driving Factors, Challenges, Trade Analysis, Price Analysis, Supply-Chain Analysis, Competitive Landscape, Company Strategies Customization 10% free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed Post-Sale Support 4 analyst hours, available up to 4 weeks Delivery Format The Latest Updated PDF and Excel Datafile

Published:May-2025

Biosimilars Market Analysis and Outlook Report: Industry Size, Share, Growth Trends, and Forecast (2025-2034)

The biosimilars market is experiencing a period of rapid growth and evolution, driven by the increasing demand for affordable alternatives to expensive biologic drugs. Biosimilars are highly similar versions of existing biologic drugs, offering a cost-effective option for treating a wide range of diseases while maintaining the same efficacy and safety profiles as the original reference products. The market is fueled by a confluence of factors, including rising healthcare costs, growing pressure to increase affordability in healthcare systems, and the increasing adoption of biosimilars by both healthcare providers and patients. In 2024, the biosimilars market witnessed significant progress with the approval of new biosimilars, the expansion of the market into new therapeutic areas, and the increasing adoption of biosimilars by payers and prescribers. This trend signifies the growing recognition of biosimilars as a valuable solution for enhancing healthcare affordability and expanding access to innovative therapies. Looking ahead to 2025, the biosimilars market is poised for continued robust growth. The increasing number of biologic drugs coming off patent, coupled with the growing need for cost-effective healthcare solutions, is expected to fuel market expansion. The market is likely to see a greater emphasis on the development of biosimilars for complex therapeutic areas, such as oncology and autoimmune diseases, expanding the availability of affordable treatment options for these conditions. Furthermore, advancements in biosimilar development and manufacturing technologies are likely to enhance the quality and consistency of biosimilars, further increasing confidence in these products among healthcare providers and patients. However, the industry will also face challenges related to the complexities of biosimilar development, the need for robust clinical trial data to demonstrate similarity to reference products, and the potential for intellectual property disputes. The biosimilars market is therefore at a critical juncture, navigating the challenges and opportunities of a rapidly evolving landscape to achieve its potential for increasing access to affordable and effective biologic therapies. The Global Biosimilars Market Analysis Report will provide a comprehensive assessment of business dynamics, offering detailed insights into how companies can navigate the evolving landscape to maximize their market potential through 2034. This analysis will be crucial for stakeholders aiming to align with the latest industry trends and capitalize on emerging market opportunities. Biosimilars Market Strategy, Price Trends, Drivers, Challenges and Opportunities to 2034 In terms of market strategy, price trends, drivers, challenges, and opportunities from2025 to 2034, Biosimilars market players are directing investments toward acquiring new technologies, securing raw materials through efficient procurement and inventory management, enhancing product portfolios, and leveraging capabilities to sustain growth amidst challenging conditions. Regional-specific strategies are being emphasized due to highly varying economic and social challenges across countries. Factors such as global economic slowdown, the impact of geopolitical tensions, delayed growth in specific regions, and the risks of stagflation necessitate a vigilant and forward-looking approach among Biosimilars industry players. Adaptations in supply chain dynamics and the growing emphasis on cleaner and sustainable practices further drive strategic shifts within companies. The market study delivers a comprehensive overview of current trends and developments in the Biosimilars industry, complemented by detailed descriptive and prescriptive analyses for insights into the market landscape until 2034. North America Biosimilars Market Analysis The North America Biosimilars market demonstrated robust growth in 2024, driven by advancements in personalized medicine, the proliferation of digital health solutions, and increased investment in biotechnologies such as biosimilars, biologics CDMO, and AI-driven medical diagnostics. The market is set to expand further in 2025, with a healthy CAGR driven by the rise in chronic disease incidence, aging demographics, and government initiatives supporting pharmaceutical innovation. Other notable growth drivers to 2034 include advancements in therapeutics and diagnostics, including biomarkers and gene therapy, as well as expanding applications of AI in drug discovery and clinical decision-making. Regulatory approvals and strategic partnerships between key players are enabling faster commercialization of cutting-edge therapies and medical technologies. This Biosimilars market growth trajectory reflects a dynamic market landscape, with innovation, demand for digital transformation, and regulatory adaptation playing pivotal roles. Europe Biosimilars Market Outlook The European Biosimilars market witnessed steady growth in 2024, underpinned by increased funding for healthcare innovation, robust R&D, and the adoption of advanced diagnostic solutions. The Biosimilars market is projected to continue growth in 2025, driven by the region's aging population and rising prevalence of autoimmune diseases. Key trends include the expansion of biostimulants and biotechnology, enhanced clinical trial imaging, and the adoption of AI-based diagnostic tools. Government policies promoting digital transformation in healthcare and incentives for eco-friendly medical plastics further support market expansion. Europe remains a hub for groundbreaking innovations, with collaborative frameworks facilitating faster regulatory approvals and market entry. Asia-Pacific Biosimilars Market Forecast Asia-Pacific’s Biosimilars market emerged as a high-growth region in 2024, driven by escalating demand for affordable healthcare solutions, rapid advancements in biotechnology, and the integration of AI in drug discovery and diagnostics. The Biosimilars market is poised for exponential growth from 2025 to 2034, supported by increasing healthcare expenditure, a rising middle class, and government initiatives fostering local manufacturing of biosimilars and biologics. Expansion in therapeutics, cell therapy, and autoimmune disease diagnostics underscores the region's focus on precision medicine. Key markets such as China, India, and Japan are spearheading innovation, bolstered by favorable policies and global collaborations. The region’s adoption of digital therapeutics and clinical trial technologies marks a transformative phase, positioning Asia-Pacific as a critical player in the global Biosimilars market landscape. Middle East, Africa, Latin America Biosimilars Market Overview The Biosimilars market across Middle East, Africa and South America displayed notable growth in 2024, particularly in emerging economies fueled by improving healthcare infrastructure and rising pharmaceutical investments. Growth from 2025 to 2034 is expected to accelerate, driven by increasing demand for affordable diagnostics, biosimilars, and vaccines to combat infectious and chronic diseases. Countries in the Middle East, Africa, and South America are witnessing significant advancements in areas like antimicrobial susceptibility testing, digital health solutions, and medical plastics. Government-led healthcare reforms, international partnerships, and a focus on localized production are key growth enablers. Additionally, the uptake of AI-driven diagnostics, eClinical solutions, and cancer therapeutics signals a shift towards innovative healthcare delivery. These trends highlight the potential of RoW markets as pivotal contributors to global healthcare evolution. Biosimilars Market Dynamics and Future Analytics The research analyses the Biosimilars parent market, derived market, intermediaries’ market, raw material market, and substitute market are all evaluated to better prospect the Biosimilars market outlook. Geopolitical analysis, demographic analysis, and Porter’s five forces analysis are prudently assessed to estimate the best Biosimilars market projections. Recent deals and developments are considered for their potential impact on Biosimilars's future business. Other metrics analyzed include the Threat of New Entrants, Threat of New Substitutes, Product Differentiation, Degree of Competition, Number of Suppliers, Distribution Channel, Capital Needed, Entry Barriers, Govt. Regulations, Beneficial Alternative, and Cost of Substitute in Biosimilars market. Biosimilars trade and price analysis helps comprehend Biosimilars's international market scenario with top exporters/suppliers and top importers/customer information. The data and analysis assist our clients in planning procurement, identifying potential vendors/clients to associate with, understanding Biosimilars price trends and patterns, and exploring new Biosimilars sales channels. The research will be updated to the latest month to include the impact of the latest developments such as the Russia-Ukraine war on the Biosimilars market. Biosimilars Market Structure, Competitive Intelligence and Key Winning Strategies The report presents detailed profiles of top companies operating in the Biosimilars market and players serving the Biosimilars value chain along with their strategies for the near, medium, and long term period. OGAnalysis’ proprietary company revenue and product analysis model unveils the Biosimilars market structure and competitive landscape. Company profiles of key players with a business description, product portfolio, SWOT analysis, Financial Analysis, and key strategies are covered in the report. It identifies top-performing Biosimilars products in global and regional markets. New Product Launches, Investment & Funding updates, Mergers & Acquisitions, Collaboration & Partnership, Awards and Agreements, Expansion, and other developments give our clients the Biosimilars market update to stay ahead of the competition. Company offerings in different segments across Asia-Pacific, Europe, the Middle East, Africa, and South and Central America are presented to better understand the company strategy for the Biosimilars market. The competition analysis enables users to assess competitor strategies and helps align their capabilities and resources for future growth prospects to improve their market share. Biosimilars Market Research Scope • Global Biosimilars market size and growth projections (CAGR), 2024- 2034 • Policies of USA New President Trump, Russia-Ukraine War, Israel-Palestine, Middle East Tensions Impact on the Biosimilars Trade and Supply-chain • Biosimilars market size, share, and outlook across 5 regions and 27 countries, 2023- 2034 • Biosimilars market size, CAGR, and Market Share of key products, applications, and end-user verticals, 2023- 2034 • Short and long-term Biosimilars market trends, drivers, restraints, and opportunities • Porter’s Five Forces analysis, Technological developments in the Biosimilars market, Biosimilars supply chain analysis • Biosimilars trade analysis, Biosimilars market price analysis, Biosimilars supply/demand • Profiles of 5 leading companies in the industry- overview, key strategies, financials, and products • Latest Biosimilars market news and developments The Biosimilars Market international scenario is well established in the report with separate chapters on North America Biosimilars Market, Europe Biosimilars Market, Asia-Pacific Biosimilars Market, Middle East and Africa Biosimilars Market, and South and Central America Biosimilars Markets. These sections further fragment the regional Biosimilars market by type, application, end-user, and country. Regional Insights North America Biosimilars market data and outlook to 2034 United States Canada Mexico Europe Biosimilars market data and outlook to 2034 Germany United Kingdom France Italy Spain BeNeLux Russia Asia-Pacific Biosimilars market data and outlook to 2034 China Japan India South Korea Australia Indonesia Malaysia Vietnam Middle East and Africa Biosimilars market data and outlook to 2034 Saudi Arabia South Africa Iran UAE Egypt South and Central America Biosimilars market data and outlook to 2034 Brazil Argentina Chile Peru * We can include data and analysis of additional coutries on demand Who can benefit from this research The research would help top management/strategy formulators/business/product development/sales managers and investors in this market in the following ways 1. The report provides 2024 Biosimilars market sales data at the global, regional, and key country levels with a detailed outlook to 2034 allowing companies to calculate their market share and analyze prospects, uncover new markets, and plan market entry strategy. 2. The research includes the Biosimilars market split into different types and applications. This segmentation helps managers plan their products and budgets based on the future growth rates of each segment 3. The Biosimilars market study helps stakeholders understand the breadth and stance of the market giving them information on key drivers, restraints, challenges, and growth opportunities of the market and mitigating risks 4. This report would help top management understand competition better with a detailed SWOT analysis and key strategies of their competitors, and plan their position in the business 5. The study assists investors in analyzing Biosimilars business prospects by region, key countries, and top companies' information to channel their investments. Available Customizations The standard syndicate report is designed to serve the common interests of Biosimilars Market players across the value chain and include selective data and analysis from entire research findings as per the scope and price of the publication. However, to precisely match the specific research requirements of individual clients, we offer several customization options to include the data and analysis of interest in the final deliverable. Some of the customization requests are as mentioned below – Segmentation of choice – Our clients can seek customization to modify/add a market division for types/applications/end-uses/processes of their choice. Biosimilars Pricing and Margins Across the Supply Chain, Biosimilars Price Analysis / International Trade Data / Import-Export Analysis, Supply Chain Analysis, Supply – Demand Gap Analysis, PESTLE Analysis, Macro-Economic Analysis, and other Biosimilars market analytics Processing and manufacturing requirements, Patent Analysis, Technology Trends, and Product Innovations Further, the client can seek customization to break down geographies as per their requirements for specific countries/country groups such as South East Asia, Central Asia, Emerging and Developing Asia, Western Europe, Eastern Europe, Benelux, Emerging and Developing Europe, Nordic countries, North Africa, Sub-Saharan Africa, Caribbean, The Middle East and North Africa (MENA), Gulf Cooperation Council (GCC) or any other. Capital Requirements, Income Projections, Profit Forecasts, and other parameters to prepare a detailed project report to present to Banks/Investment Agencies. Customization of up to 10% of the content can be done without any additional charges. Note: Latest developments will be updated in the report and delivered within 2 to 3 working days

Published:Feb-2025

Omega-3 Fatty Acids Market Analysis and Outlook Report: Industry Size, Share, Growth Trends, and Forecast (2025-2032)

Omega-3 fatty acids are essential polyunsaturated fats, primarily including alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). These nutrients are vital for maintaining heart health, supporting brain function, and reducing inflammation. They are commonly found in fish oils, certain plant oils, and are also available as dietary supplements. Market Insights: Rising Consumer Awareness: There's an increasing global recognition of the health benefits associated with omega-3 fatty acids, leading to higher consumption of supplements and fortified foods. Diversification of Sources: Due to sustainability concerns and dietary preferences, there's a notable shift toward plant-based and algal sources of omega-3s, catering to vegetarian and vegan consumers. Product Innovation: Manufacturers are developing new formulations and delivery methods, such as gummies, emulsions, and fortified foods, to enhance bioavailability and consumer appeal. Prevalence of Chronic Diseases: The rising incidence of cardiovascular diseases and mental health disorders has led to a greater emphasis on preventive healthcare, boosting the demand for omega-3 supplements. Aging Population: An increasing elderly demographic seeks omega-3s for their potential benefits in cognitive health and reducing age-related ailments. Regulatory Support: Government initiatives and health organizations are endorsing the consumption of omega-3s, further propelling market growth. Report Scope Table body { font-family: Arial, sans-serif; padding: 20px; background-color: #f9f9f9; } table { width: 80%; border-collapse: collapse; margin-top: 20px; background-color: #FFFFFF; /* white shade */ table-layout: fixed; /* Ensures equal column widths */ } th, td { padding: 10px; border: 1px solid #ccc; vertical-align: top; width: 50%; /* Equal column width */ } th { background-color: #cce6ff; /* Slightly darker blue for header */ text-align: left; } .upload-section { margin-top: 30px; } Report Scope Overview Report Scope Details Base Year 2024 Compound Annual Growth Rate (CAGR) (%) 2025 to 2034 Market Forecast Period 2025 to 2034 Market Forecast Units USD Billion Segments Covered By Type, By Source, By Application and By Distribution Channel Region Covered North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa Countries Covered USA, Canada, Mexico Germany, UK, France, Spain, Italy, China, India, Japan, Australia, South Korea, Saudi Arabia, UAE, Iran, South Africa, Brazil, Argentina Key Companies Profiled BASF SE, Cargill, Incorporated, DSM, ADM, Kerry Group Plc, Croda International Plc, Orkla, Corbion, Aker BioMarine, Polaris, Epax Norway AS, Lonza Group, Golden Omega, Omega Protein Corporation, GC Rieber Oils Customization Scope 10% Free Customization Post-Sale Analyst Support 4 Weeks Delivery Format PDF and Excel via Email (PPT/Word available on special request)

Published:Apr-2025